Overactive Bladder
Conditions
Keywords
Vibegron, Urinary bladder, overactive, Beta-3 adrenergic receptor (β3-AR) agonists, Urge urinary incontinence, OAB
Brief summary
This study will evaluate the treatment satisfaction, discontinuation, reasons for discontinuation, quality of life, healthcare resource utilization, and safety with Vibegron for the treatment of OAB in the context of real-world clinical practice.
Interventions
DRUGVibegron
Vibegron to be administered.
Sponsors
Urovant Sciences GmbH
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Diagnosis of overactive bladder (OAB) with or without urgency urinary incontinence * Symptoms of OAB for at least 3 months prior to the Baseline Visit * Willing and able to complete electronic patient-reported outcomes questionnaires monthly for a minimum of 1 year * Previous exposure to anticholinergics or mirabegron monotherapy and/or mirabegron plus solifenacin combination therapy prior to initiation of vibegron
Exclusion criteria
* Any contraindication to the use of vibegron per the United States label * History of OAB treatment with botulinum toxin A; sacral neuromodulation; percutaneous tibial nerve stimulation; external beam radiation therapy; urinary stents within the last 6 months; pelvic or lower urinary tract surgery within the last 6 months; and urethral catheterizations within the last 3 months prior to the Baseline Visit * History of mixed incontinence where stress incontinence is the predominant form (as determined by the investigator) * Participants at risk of urinary retention (as determined by the investigator) * Neurologic conditions associated with OAB symptoms, e.g., multiple sclerosis * Pregnant or breastfeeding or plans to do so during the study * Use of vibegron prior to the Baseline Visit either prescribed or in a previous vibegron clinical trial where the participant was on vibegron * Anyone who, at the discretion of the investigator, is not suitable for treatment with a beta 3 agonist for OAB for any reason
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mean Satisfaction Domain Score as Assessed by the Overactive Bladder Satisfaction with Treatment Questionnaire (OAB-SAT-q) | Month 3 | The OAB-SAT-q is an 11-item questionnaire designed to assess participant's satisfaction with overactive bladder treatment in the clinical setting. It includes 3 subscales (satisfaction, side effects, endorsement) and 2 single-item assessments (convenience, preference), with a 4-week recall period. The OAB-SAT-q is scored by domains ranging from 0-100. Scores for the Convenience item range from 0-100. The Preference item is calculated as a percentage. Higher scores indicate higher levels of treatment satisfaction, endorsement, and convenience. |
| Mean Satisfaction Domain Score as Assessed by the OAB-SAT-q | Month 6 | The OAB-SAT-q is an 11-item questionnaire designed to assess participant's satisfaction with overactive bladder treatment in the clinical setting. It includes 3 subscales (satisfaction, side effects, endorsement) and 2 single-item assessments (convenience, preference), with a 4-week recall period. The OAB-SAT-q is scored by domains ranging from 0-100. Scores for the Convenience item range from 0-100. The Preference item is calculated as a percentage. Higher scores indicate higher levels of treatment satisfaction, endorsement, and convenience. |
Secondary
| Measure | Time frame |
|---|---|
| Number of Participants with Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) | Up to Month 12 |
| Mean Duration of Vibegron Treatment | Month 3, Month 6 and Month 12 |
| Percentage of Positive Responders to Individual Treatment Satisfaction Questions 1-3 and 11 as Assessed by the OAB-SAT-q | Month 3, Month 6 and Month 12 |
| Percentage of Participants Discontinuing Vibegron Treatment for the Indicated Reasons | Month 3, Month 6 and Month 12 |
| Number of Participants Discontinuing Vibegron Treatment for the Indicated Reasons | Month 3, Month 6 and Month 12 |
| Mean Scores on the Side Effects, Endorsement, Convenience, and Preference Domains as Assessed by the OAB-SAT-q | Month 3, Month 6 and Month 12 |
Countries
United States
Outcome results
None listed